Bibliography
- Reilly SM, Lee CH. PPAR-delta as a therapeutic target in metabolic disease. FEBS Lett 2008;582:26-31
- Takahashi S, Tanaka T, Sakai J. New therapeutic target for metabolic syndrome: PPAR-delta. Endocr J 2007;54:347-57
- Seedorf U, Aberle J. Emerging roles of PPAR-delta in metabolism. Biochim Biophys Acta 2007;1771:1125-31
- Kang K, Hatano B, Lee CH. PPAR delta agonists and metabolic diseases. Curr Atheroscler Rep 2007;9:72-7
- Furnsinn C, Willson TM, Brunmair B. Peroxisome proliferator-activated receptor-delta, a regulator of oxidative capacity, fuel switching and cholesterol transport. Diabetologia 2007;50:8-17
- Takahashi S, Tanaka T, Kodama T, Sakai J. Peroxisome proliferator-activated receptor delta (PPAR-delta), a novel target site for drug discovery in metabolic syndrome. Pharmacol Res 2006;53:501-7
- Barish GD, Narkar VA, Evans RM. PPAR-delta: a dagger in the heart of the metabolic syndrome. J Clin Invest 2006;116:590-7
- Berger J, Leibowitz MD, Doebber TW, et al. Novel peroxisome proliferator-activated receptor (PPAR)-gamma and PPAR-delta ligands produce distinct biological effects. J Biol Chem 1999;274:6718-25
- Leibowitz MD, Fievet C, Hennuyer N, et al. Activation of PPAR-delta alters lipid metabolism in db/db mice. FEBS Lett 2000;473:333-6
- Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. J Med Chem 2000;43:527-50
- Oliver WR Jr, Shenk JL, Snaith MR, et al. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 2001;98:5306-11
- Wallace JM, Schwarz M, Coward P, et al. Effects of peroxisome proliferator-activated receptor alpha/delta agonists on HDL-cholesterol in vervet monkeys. J Lipid Res 2005;46:1009-16
- Lee CH, Chawla A, Urbiztondo N, et al. Transcriptional repression of atherogenic inflammation: modulation by PPAR-delta. Science 2003;302:453-7
- Li AC, Binder CJ, Gutierrez A, et al. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPAR-alpha, beta/delta, and gamma. J Clin Invest 2004;114:1564-76
- Vosper H, Khoudoli GA, Palmer CN. The peroxisome proliferator activated receptor delta is required for the differentiation of THP-1 monocytic cells by phorbol ester. Nucl Recept 2003;1:9
- Graham TL, Mookherjee C, Suckling KE, et al. The PPAR-delta agonist GW0742X reduces atherosclerosis in LDLR(-/-) mice. Atherosclerosis 2005;181:29-37
- Barish GD, Atkins AR, Downes M, et al. PPAR-delta regulates multiple proinflammatory pathways to suppress atherosclerosis. Proc Natl Acad Sci USA 2008;105:4271-6
- Takata Y, Liu J, Yin F, et al. PPAR-delta-mediated anti-inflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis. Proc Natl Acad Sci USA 2008;105:4277-82
- Kilgore KS, Billin AN. PPAR-beta/delta ligands as modulators of the inflammatory response. Curr Opin Investig Drugs 2008;9:463-9
- Tanaka T, Yamamoto J, Iwasaki S, et al. Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci USA 2003;100:15924-9
- Lee CH, Olson P, Hevener A, et al. PPAR-delta regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci USA 2006;103:3444-9
- Cheng L, Ding G, Qin Q, et al. Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat Med 2004;10:1245-50
- Burkart EM, Sambandam N, Han X, et al. Nuclear receptors PPAR-beta/delta and PPAR-alpha direct distinct metabolic regulatory programs in the mouse heart. J Clin Invest 2007;117:3930-9
- Planavila A, Rodriguez-Calvo R, Jove M, et al. Peroxisome proliferator-activated receptor beta/delta activation inhibits hypertrophy in neonatal rat cardiomyocytes. Cardiovasc Res 2005;65:832-41
- Ding G, Cheng L, Qin Q, et al. PPAR-delta modulates lipopolysaccharide-induced TNF-alpha inflammation signaling in cultured cardiomyocytes. J Mol Cell Cardiol 2006;40:821-8
- Jucker BM, Doe CP, Schnackenberg CG, et al. PPAR-delta activation normalizes cardiac substrate metabolism and reduces right ventricular hypertrophy in congestive heart failure. J Cardiovasc Pharmacol 2007;50:25-34
- Sprecher DL, Massien C, Pearce G, et al. Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator-activated receptor delta agonist. Arterioscler Thromb Vasc Biol 2007;27:359-65
- Sprecher DL, Johnson A, Pearce G, Watts G, Barrett P. Lipid and lipoprotein metabolism: clinical 2. Effects of a peroxisome proliferator activated receptor (PPAR) delta agonist on apolipoprotein B-100 kinetics in the metabolic syndrome [presentation number 1211; session number AOP.15.2]. American Heart Association Scientific Sessions 2005
- Riserus U, Sprecher D, Johnson T, et al. Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes 2008;57:332-9
- Guha M, Deng M, Duron S, et al. Selective activation of peroxisome proliferator-activated receptor β/δ holds promise for the treatment of obesity, metabolic syndrome and diabesity. Available from: http://www.kalypsys.com/media/presentations/PPAR%202006%20ADA.pdf [Last accessed July 2008]
- Rubenstrunk A, Hanf R, Hum DW, et al. Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta 2007;1771:1065-81
- Shearer BG, Billin AN. The next generation of PPAR drugs: do we have the tools to find them? Biochim Biophys Acta 2007;1771:1082-93
- Howes LG, Kostner K. The withdrawal of torcetrapib from drug development: implications for the future of drugs that alter HDL metabolism. Expert Opin Investig Drugs 2007;16:1509-16
- Schmuth M, Jiang YJ, Dubrac S, et al. Peroxisome proliferator-activated receptors (PPAR) and liver X receptors (LXR) in epidermal biology. J Lipid Res 2008;49(3):499-509
- Michalik L, Wahli W. Peroxisome proliferator-activated receptors (PPARs) in skin health, repair and disease. Biochim Biophys Acta 2007;1771:991-8
- Kim DJ, Bility MT, Billin AN, et al. PPAR-beta/delta selectively induces differentiation and inhibits cell proliferation. Cell Death Differ 2006;13:53-60
- Kim DJ, Murray IA, Burns AM, et al. Peroxisome proliferator-activated receptor-beta/delta inhibits epidermal cell proliferation by down-regulation of kinase activity. J Biol Chem 2005;280:9519-27
- De La Monte SM, Tong M, Lester-Coll N, et al. Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease. J Alzheimers Dis 2006;10:89-109